Hemoglobinopathies Clinical Trials

8 recruiting

Hemoglobinopathies Trials at a Glance

8 actively recruiting trials for hemoglobinopathies are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in New York, St Louis, and Charlotte. Lead sponsors running hemoglobinopathies studies include Masonic Cancer Center, University of Minnesota, Washington University School of Medicine, and Memorial Sloan Kettering Cancer Center.

Browse hemoglobinopathies trials by phase

Treatments under study

About Hemoglobinopathies Clinical Trials

Looking for clinical trials for Hemoglobinopathies? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hemoglobinopathies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hemoglobinopathies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

HemoglobinopathiesMetabolic DisordersHematologic, Immune, or Bone Marrow Disorders+1 more
Washington University School of Medicine220 enrolled28 locationsNCT00920972
Recruiting
Phase 3

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Beta-ThalassemiaSickle Cell DiseaseHematologic Diseases+4 more
Vertex Pharmaceuticals Incorporated26 enrolled6 locationsNCT05477563
Recruiting
Phase 2

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

AMLMDSHLH+6 more
Memorial Sloan Kettering Cancer Center31 enrolled1 locationNCT04644016
Recruiting
Phase 2

Allo HSCT for High Risk Hemoglobinopathies

Sickle Cell DiseaseHemoglobinopathiesGraft Failure
Masonic Cancer Center, University of Minnesota62 enrolled1 locationNCT06872333
Recruiting
Phase 1Phase 2

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

HemoglobinopathiesBone Marrow Failure SyndromesMetabolic Disorders+3 more
Washington University School of Medicine29 enrolled4 locationsNCT03128996
Recruiting

Discarded Bone Marrow for Hematology Research

Hemoglobinopathies
St. Jude Children's Research Hospital50 enrolled1 locationNCT04671212
Recruiting
Not Applicable

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

HemoglobinopathiesImmunodeficienciesHematologic Disorders
Masonic Cancer Center, University of Minnesota30 enrolled1 locationNCT01666080
Recruiting
Early Phase 1

Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease

Hereditary DiseasesHemoglobinopathiesAlpha Thalassemia Hemoglobin H Constant Spring
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army5 enrolled1 locationNCT06107400